Cagrilintide and CJC-1295 (without DAC) Interaction

Synergistic
Mechanism-based 51% confidence

Cagrilintide and CJC-1295 (without DAC) have a synergistic interaction with 51% confidence. Cagrilintide helps counteract the insulin-disrupting effects of CJC-1295 (without DAC). A smart combination — the insulin sensitizer mitigates metabolic side effects. Both compounds affect the gi tract, so monitoring these systems is recommended.

Compound Profiles

Cagrilintide

Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes

Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.

Half-life: ~7 days (159-195 hours) Typical dose: 2.4mg weekly (after escalation) weight loss, metabolic
amylin receptor cardiotoxicinsulin sensitizing
View full profile

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pancreas
low
Pituitary
low

Frequently Asked Questions

Can I take Cagrilintide with CJC-1295 (without DAC)?

Yes, Cagrilintide and CJC-1295 (without DAC) can generally be taken together. Cagrilintide helps counteract the insulin-disrupting effects of CJC-1295 (without DAC). A smart combination — the insulin sensitizer mitigates metabolic side effects.

Is Cagrilintide and CJC-1295 (without DAC) safe together?

Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.

What are the interactions between Cagrilintide and CJC-1295 (without DAC)?

Cagrilintide helps counteract the insulin-disrupting effects of CJC-1295 (without DAC). A smart combination — the insulin sensitizer mitigates metabolic side effects. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time Cagrilintide and CJC-1295 (without DAC)?

Cagrilintide has a half-life of ~7 days (159-195 hours) and CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Cagrilintide vs CJC-1295 (without DAC)

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.